Henry M. Rinder, MD Associate Professor of Laboratory Medicine and Internal Medicine Associate Director, Immunology and Flow Cytometry Laboratories Associate Director, Hematology Laboratories Director, Coagulation Laboratory Co-director, Yale Pathology Residency Program Director, Clinical Pathology Residency Training Director, Laboratory Medicine Cases On-Line Fitkin 617 Phone: 203-688-8176 Fax: 203-688-4111 e-mail: henry.rinder@yale.edu

M.D., University of Vermont College of Medicine, 1984
B.S., Yale College, 1979
Residencies and Fellowships: Maine Medical Center, Portland, ME; Yale University and Yale-New Haven Hospital, New Haven, CT

Community of Science Biosketch

 

Research Interests

Dr. Rinder's research interests primarily revolve around cellular coagulation and platelet physiology in two related areas. First, the laboratory investigates the biology of platelet activation and subsequent leukocyte-platelet adhesive interactions. Our laboratory has investigated the responsible receptor-ligand pairs, the adhesive alterations as a result of signal transduction, and differences in functional cell adhesion based on cell lineage and phenotype. This bench investigation has led the laboratory into studying the mechanisms of platelet and leukocyte activation during platelet storage and in the setting of extracorporeal circulation. During extracorporeal circulation, the complement system plays a major role in stimulating cellular events and this, in turn, has led to investigations of specific complement component blockade.

References

1. Rinder HM, Tracey JL, Rinder CS, Leitenberg D, Smith BR. Neutrophil but not monocyte activation inhibits P-selectin-mediated platelet adhesion. Thromb Haemost 72:750-56, 1994
2. Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA. Blockade of C5 and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 96:1564, 1995.
3. Tracey JB, Rinder HM. Characterization of the P-selectin ligand on human hematopoietic progenitors. Exp Hematol 24:1494-1500, 1996.
4. Smith BR and Rinder HM. Interactions of Platelets and Endothelial Cells with Erythrocytes and Leukocytes in TTP. Sem Hematol 34:90-97, 1997.
5. Rinder HM, Ault KA. Platelet activation and its detection during the preparation of platelets for transfusion. Transfus Med Rev 12:271-287, 1998.
6. Rinder CS, Rinder HM, Johnson K, Smith M, Lee D, Tracey J, Polock G, Higgins P, Yeh CG, Smith BR. 1999. Role of C3 Cleavage in Monocyte Activation during Extracorporeal Circulation. Circulation 100:553-558, 1999.
7. Rinder CS, Rinder HM, Smith MJ, Tracey JB, Fitch JCK, Li L, Rollins SA, Smith BR. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J Thor Cardiovasc Surgery 118:460-466, 1999.
8. Fitch JCK, Rollins S, Matis L, Alford B, Aranki S, Collard CD, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O'Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, Sherman SK. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 100:2499-2506, 1999.
9. Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. In Current Opinion in Hematology, Stossel TP and Sandler SG, eds. 6:437-441, 1999.
10. Rinder HM, Rinder CS. Preservation of platelet function after cardiac
    surgery and apheresis. In Platelet therapy: current status and future challenges. Seghatchian J, Snyder EL, and Krailadsiri P, eds. Elsevier Science, Amsterdam pp.169-198, 2000.
11. Margolin A, Avants SK, Setaro J, Rinder HM, Grupp, L. Cocaine, HIV, and their cardiovascular effects: Is there a role for ACE-inhibitor therapy? Drug and Alcohol Dependence 61:35-45, 2000.
12. Perez LE, Rinder HM, Wang C, Tracey JB, Maun N, Krause D. Xenotransplantation of immunodeficient mice with human blood CD34+ cells provides an in-vivo model for human megakaryocytopoiesis and platelet production. Blood 97:1635-43, 2001
13. Griffin MJ, Rinder HM, Smith BR, Tracey JB, Kriz NS, Li CK, Rinder CS.The Effects of Heparin, Protamine, and Heparin/Protamine Reversal on Platelet Function Under Conditions of Arterial Shear Stress. Anesth Analg 93:20 –7, 2001

Our second area of interest has been the detection of that subset of platelets which is most recently released from the circulation ("reticulated platelets"), analogous to red cell reticulocytes. Enumeration of reticulated platelets has allowed our laboratory to explore platelet kinetic diagnostics in patients with different etiologies of thrombocytopenia, in patients with thrombotic disorders, and in those recovering from marrow injury. These studies have also led to bench studies of reticulated platelet function in order to discern the differential hemostatic potential of the youngest circulating platelets.

References

1. Rinder HM, Bonan JL, Anandan S, Rinder CS, Rodrigues PA, Smith BR: Non-invasive measurement of platelet kinetics in normal and preeclamptic pregnancies. Am J Obstet Gynecol 170:117-22, 1994
2. Peterec SM, Brennan SA, Rinder HM, Winek JL, Beardsley DL. Reticulated platelet values in normal and thrombocytopenic neonates. J Peds 129:269-74, 1996.
3. Rinder HM, Schuster, JE, Rinder CS, Wang C, Schweidler HJ, Smith BR. Correlation of Thrombosis with Increased Platelet Turnover in Thrombocytosis. Blood 91:1288-1294, 1998.
4. Rinder HM. Tracey JB. Recht M. DeCastro L. Rinder CS. McHugh C. Smith BR. Differences in platelet alpha-granule release between normals and immune thrombocytopenic patients and between young and old platelets. Thrombosis & Haemostasis. 80(3):457-62, 1998.
5. Rinder HM. Platelet kinetics and hemostasis. In Rossi's Principles of Transfusion Medicine, 3rd ed. Simon, Dzik, Snyder, Stowell, and Strauss eds. Lippincott, Williams, & Wilkins, Philadelphia (in press)

The laboratory accepts graduate students directly through the Yale Program in Biomedical Engineering or as an adjunct laboratory through the Graduate School Combined Programs in Biological and Biomedical Sciences. Post-doctoral fellows (MD, PhD or MD/PhD) are also accepted, most commonly through the Departments of Laboratory Medicine, Pathology, Internal Medicine/Hematology, Internal Medicine/Oncology, Anesthesiology, Pediatrics/Hematology-Oncology, or Pediatrics/Infectious Diseases. Yale medical students may elect to work in the laboratory through the standard thesis mechanism and Yale undergraduate students may apply through the Molecular Biochemistry and Biophysics course 470a and 471b. To e-mail Dr. Rinder, please click here.

Clinical and Teaching Activities

Dr. Rinder sees adult hematology/oncology patients and carries out pathology interpretative clinical work through the Yale Faculty Practice. Dr. Rinder is actively involved in teaching at the graduate level through the Laboratory Medicine and Hematology teaching programs at the Yale School of Medicine. Dr. Rinder also teaches residents, fellows, postdoctoral and graduate students and at continuing education courses organized through the Yale Cancer Center, and the Departments of Internal Medicine and Laboratory Medicine.